about
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.Onco-nephrology: current concepts and future perspectives.Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.IgA-Dominant Glomerulopathy and Thrombotic Microangiopathy After Chemotherapy.
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Gemcitabine-induced thrombotic microangiopathy.
@ast
Gemcitabine-induced thrombotic microangiopathy.
@en
type
label
Gemcitabine-induced thrombotic microangiopathy.
@ast
Gemcitabine-induced thrombotic microangiopathy.
@en
prefLabel
Gemcitabine-induced thrombotic microangiopathy.
@ast
Gemcitabine-induced thrombotic microangiopathy.
@en
P2860
P356
P1476
Gemcitabine-induced thrombotic microangiopathy.
@en
P2093
P2860
P304
P356
10.1111/IMJ.12261
P577
2013-11-01T00:00:00Z